Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients

Fred Poordad, Carmen Landaverde

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

The treatment of chronic hepatitis C is a rapidly changing arena with new medications, new guidelines, and an evolving understanding of the virus, host factors and natural history. With the explosion of new information, the educational infrastructure to update clinicians has been outpaced; many feel uncertain if the tools they are using to care for patients are meeting the standard of practice. This review focuses on the most common genotype of the hepatitis C virus and the rules of engagement when treating with pegylated interferon and ribavirin. Viral assessment guideposts are evaluated and put into context for a clinical audience. The expected arrival of newer antiviral therapies is still years away, and maximizing the current treatment regimens is of utmost importance to eradicate virus when feasible, while minimizing toxicity.

Original languageEnglish (US)
Pages (from-to)91-97
Number of pages7
JournalTherapeutic Advances in Gastroenterology
Volume2
Issue number2
DOIs
StatePublished - Mar 2009
Externally publishedYes

Keywords

  • Early virologic response
  • Hepatitis C virus
  • Negative predictive value
  • Pegylated interferon
  • Positive predictive value
  • Rapid virologic response
  • Relapse
  • Ribavirin

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients'. Together they form a unique fingerprint.

Cite this